• PDF: Delivered by email usually within 4 to 8 UK business hours.
  • PRINT/CD-ROM: Despatched within 1 to 2 working days.

CNS Drug Discoveries: Neurodegenerative Disorders

  • Publication Date:November 2006
  • Publisher:Espicom
  • Product Type: Report
  • Pages:127

CNS Drug Discoveries: Neurodegenerative Disorders

Focusing on Alzheimer's Disease

Over the last 3 years, the value of the Alzheimer's disease market has grown by an average of 19% per year. Growth has been driven by increasing availability and reimbursement of Alzheimer's drugs. There are considerable opportunities within these markets due to an ageing population and the high unmet clinical need, particularly within the late stage of disease. In addition, research over the last 20 years has increased our understanding of the underlying mechanisms of disease progression and provided new targets for drug validation resulting in a number of novel drugs in clinical trials.

Global Alzheimer's market

Nootropic drugs or anti-Alzheimer's drugs are one of the largest segments of the neurodegenerative market and accounted for 31% of global sales (US$3.0 billion in 2004 and equivalent to 5% of global CNS drug sales). The market for drugs to treat Alzheimer's disease has grown steadily since the launch of Aricept in 1996 and experienced 21% growth year-on-year in 2003.

Whilst the US accounts for approximately 50% of global Alzheimer's drug sales, the majority of growth occurred outside the US with European sales increasing to 29% of sales in 2004. This is largely due to the launch of Ebixa, the new NMDA receptor antagonist from Lundbeck/Forest, and the recognition by regulatory committees such as the NICE in the UK condoning the use of these agents in moderate-to-severe Alzheimer's disease.

The most frequently prescribed anti-Alzheimer's drug is Aricept from Eisai/Pfizer, which was launched in the major pharmaceutical markets in 1997. In 2004, Aricept generated global sales of US$1.2 billion, accounting for approximately 40% of the market by value.

Key questions answered by this chapter include:

  • What will the value of the Alzheimer's market be in 2010?
  • Will Eisai/Pfizer be able to defend their market-leading position with Aricept?
  • What are the sales prospects for Lundbeck/Forest's Namenda?
  • Which market will see the highest growth rate over the next 5 years?
  • How successful will new late-stage therapies be such as Phenserine (Axonyx), Alzhemed (Neurochem) and Flurizan (Myriad Genetics) be?
  • Executive Summary
    • THE FACTS
    • What is neurodegeneration and why are we interested in it?
  • Patient Statistics
    • Incidence, diagnosis rates and treatment; now and in the future
  • Patient Model
    • The addressable AD and PD patient population will grow by 2% per annum
    • Summary of AD patient population forecasts 2005A-2012E
    • Summary of PD patient population forecasts 2005A-2012E
    • DRUG GROWTH DRIVERS
    • DRUG GROWTH RISKS/DAMPENERS
  • Global Ad/Pd Market
    • Global CNS Market (US$68 7 billion)
  • Global Sales Split
    • AD and PD Global sales split (2005A)
    • AD Global sales split (2005A)
    • PD Global sales split (2005A)
    • US market
    • AD US drugs sales split (2005A)
    • PD US drugs sales split (2005A)
    • European market
    • AD European drugs sales split (2005A)
    • PD European drugs sales split (2005A)
    • Japan
    • Split between AD and PD in Japan (2005A)
    • The major players
    • Market Share of AD players by sales (Dec 2005A)
    • Market Share of PD players by sales (Dec 2005A)
    • Players and Products in 2012
    • Market Share of AD players by sales (Dec 2012E)
    • Players and Products in 2012
    • Market Share of PD players by sales (Dec 2012E)
  • Current Ad Treatments
  • Current Pd Treatments
    • Leading Brands
    • Comparison of leading AD drugs
    • Comparison of leading PD drug classes
    • Patent Exposure of Current Products
    • Patent Exposure of Leading AD Brands
    • Patent Exposure of Leading PD Brands
  • Analysis Of Leading Brands
    • AD Agents
    • PD Agents
    • Acetylcholine Esterase (AChE) Inhibitors
    • Aricept (Eisai)
    • Exelon (Novartis)
    • Razadyne (Johnson & Johnson/Shire)
    • NMDA Antagonist
    • Namenda/Ebixa (Forest/Lundbeck)
    • Dopamine Agonists
    • Apokyn (Britannia/Vernalis)
    • Neupro (Schwarz Pharma)
    • Sifrol/Mirapex/Mirapexin (Boehringer Ingelheim)
    • Requip (GlaxoSmithKline)
    • Monoaminoxidase (MAO) Inhibitors
    • Azilect (Lundbeck/Teva)
    • Catechol-O-Methyltransferase (COMT) Inhibitors
    • Comtan/Comtess & Stalevo (Novartis)
  • Global Sales Forecasts Of Current Treatments 2005 - 2012
    • Sales Forecasts of Current Leading AD Drugs
    • Sales Forecasts of Current Leading PD Drugs 2005 - 2012
    • Model assumptions
    • NEW DRUGS IN R&D
    • Drugs in Development to Treat AD and PD
  • Analysis Of Phase III Drugs
    • New Drugs in Phase III Development to Treat AD and PD
    • AD Agents
    • PD Agents
    • AD Agents
    • Alzhemed (Neurochem)
    • Flurizan (Myriad Genetics)
    • Phenserine (Axonyx)
    • Xaliproden (sanofi-aventis)
    • Parkinson's Disease
    • E2007 (Eisai)
    • Istradefylline (Kyowa Hakko)
    • Safinamide (Newron)
    • SLV308 (Solvay)
    • Spheramine (Schering AG/Titan)
  • Global Sales Forecasts Of Phase III Ad And Pd Drugs 2006 - 2012
    • Sales Forecasts of Phase III Developmental AD and PD Drugs
    • Model assumptions
  • Analysis Of Phase II Drugs
    • New Drugs in Early Clinical Development to Treat AD and PD
    • AD Agents
    • PD Agents
    • AD agents
    • Bapineuzumab (Wyeth/Elan)
    • Other promising Phase II drugs
    • CX717(Cortex Pharmaceuticals)
    • EVT 101 (Evotec)
    • Ketasyn (Accera)
    • MEM 1003 (Memory Pharmaceuticals)
    • PBT2 (Prana)
    • SGS-742 (Saegis Pharmaceuticals)
    • PD drugs
    • SR 57667 (sanofi-aventis)
    • Talampanel (IVAX)
    • VR040 (Vectura)
  • Competitor Ratio Analysis Products/Drugs
    • CR Analysis of AD Agents Approved by 2012 - Based on Drug Class
    • CR Analysis of PD Agents Approved by 2012 - Based on Drug Class
  • Competitor Ratio Analysis - Companies
    • CR Analysis of AD and PD Agents Approved by 2012 - Based on Company
  • Winners & Losers
    • Summary of Key Companies and Drugs in the AD and PD Market by 2012
  • Discontinuation Of Drugs
    • AD and PD drugs discontinued from clinical development
  • Neurodegenerative Appendix 1
    • Phase transition probability
    • Probability of launch
  • Neurodegenerative Appendix 2
    • AD Patient Model
    • Summary of AD Patient Population Forecasts
  • Neurodegenerative Appendix 3
    • PD Patient Model
    • Summary of PD Patient Population Forecasts
  • Neurodegenerative Appendix 4
    • Global AD Drugs Sales 2005-2012
    • Global AD Drug Sales 2005A-2012E
  • Neurodegenerative Appendix 5
    • Global PD Drugs Sales 2005-2012
    • Global PD Drug Sales 2005A-2012E
  • Neurodegenerative Appendix 6
    • Competitor Ratio Analysis Criteria
    • Key AD & PD Drugs on the Market by 2012
  • Neurodegenerative Glossary
  • Neurodegenerative References
  • Acronyms
+44 20 8816 8548

Ask a question about CNS Drug Discoveries: Neurodegenerative Disorders

Enter the characters you see in the picture below
Captcha